人民财讯1月6日电，据翔宇医疗消息，公司"一种基于医用下肢功率车的训练方法及系统"获发明专利。 该专利通过训练方法流程、动态阻力调节等技术创新，核心是实现医用下肢功率车的动态阻力自适应训 练，通过实时数据闭环确保训练在目标转速区间内平稳进行，解决传统训练中"阻力固定、响应滞后、 安全风险高"的行业痛点。 ...

格隆汇1月6日丨翔宇医疗(688626.SH)公布，近期资本市场对人脑工程、脑机接口等概念关注度较高， 相关板块股价涨幅较大。公司目前主要聚焦非侵入式脑机接口技术，覆盖作业疗法、运动疗法、认知言 语、吞咽等康复全场景布局，与当前国际上的侵入式脑机接口技术路线存在差异。公司在脑机接口方面 的投入，目前在技术、产品、渠道市场等方面形成一定的布局，但招投标和销售等具有滞后性，截至 2025年末，相关产品尚未实现规模化销售，营收占比较小。 ...

人民财讯1月6日电，据翔宇医疗消息，近日，翔宇医疗与滕州市中心人民医院共建的脑机接口神经调控 康复治疗与临床研究转化中心正式揭牌成立。该中心将重点聚焦脑卒中、脊髓损伤、认知障碍等神经系 统疾病的康复治疗与研究，精准打通"临床需求—技术研发—产品落地"的闭环链路，推动脑机接口等前 沿技术快速转化为适配临床场景的康复方案，助力患者重建大脑与肢体的功能连接，提升康复效率与生 活质量。 ...

Core Viewpoint - The company, Xiangyu Medical, has noted increased market attention on brain engineering and brain-machine interface concepts, leading to significant stock price increases in related sectors [1] Company Focus - The company primarily focuses on non-invasive brain-machine interface technology, which encompasses a comprehensive rehabilitation layout including occupational therapy, motor therapy, cognitive speech, and swallowing [1] - This approach differs from the current international trend towards invasive brain-machine interface technologies [1] Market Position and Development - The company has made investments in brain-machine interface technology, establishing a certain level of layout in technology, products, and market channels [1] - However, the company faces delays in bidding and sales processes, with related products not expected to achieve large-scale sales until the end of 2025, resulting in a small revenue contribution [1]

Group 1 - The core point of the article is that Xiangyu Medical (688626) has experienced a significant stock price fluctuation, with a cumulative increase of 30% over three consecutive trading days, triggering an abnormal trading alert according to stock exchange regulations [1] - The recent surge in interest in brain engineering and brain-computer interface concepts has positively impacted the stock prices in this sector, including Xiangyu Medical, which focuses on non-invasive brain-computer interface technology [1] - Xiangyu Medical's current technology and product development in brain-computer interfaces cover various rehabilitation scenarios, but the company acknowledges that its products are not expected to achieve large-scale sales until the end of 2025, resulting in a small revenue contribution at this time [1] Group 2 - The stock price of Xiangyu Medical reached a closing price of 87.12 yuan per share on January 6, with a 20% increase on that day, following two consecutive days of trading limits [1]

证券代码：688626 证券简称：翔宇医疗 公告编号：2026-001 河南翔宇医疗设备股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 河南翔宇医疗设备股份有限公司（以下简称"公司"）股票交易连续三 个交易日内（2025 年 12 月 31 日、2026 年 1 月 5 日、2026 年 1 月 6 日）日收盘 价格涨幅偏离值累计达到 30%，根据《上海证券交易所科创板股票上市规则》《上 海证券交易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》 的有关规定，属于股票交易异常波动情形。 经公司自查，并向控股股东、实际控制人核实，截至本公告披露日，除 公司已披露信息外，公司、公司控股股东和实际控制人不存在其他应披露而未披 露的重大信息，也不存在处于筹划阶段的重大事项。 近期资本市场对人脑工程、脑机接口等概念关注度较高，相关板块股价 涨幅较大。公司目前主要聚焦非侵入式脑机接口技术，覆盖作业疗法、运动疗法、 认知言语、吞咽等康复全场景布局，与当前国际上的侵入式脑机接 ...

Core Viewpoint - The stock of Xiangyu Medical has experienced significant volatility, with a cumulative price deviation of 30% over three consecutive trading days, attributed to heightened market interest in brain engineering and brain-computer interface concepts [1] Company Focus - The company is primarily focused on non-invasive brain-computer interface technology, which encompasses a comprehensive range of rehabilitation scenarios including occupational therapy, motor therapy, cognitive speech, and swallowing [1] - This approach differs from the current international trend towards invasive brain-computer interface technologies [1] Market Position and Development - The company has made investments in brain-computer interface technology, establishing a certain level of layout in technology, products, and market channels [1] - However, the bidding and sales processes exhibit a lag, and as of the end of 2025, related products are not expected to achieve large-scale sales, resulting in a relatively small revenue contribution [1]

Core Viewpoint - Recent market attention on brain engineering and brain-computer interface concepts has led to significant stock price increases in related sectors [1] Company Overview - The company, Xiangyu Medical, focuses on non-invasive brain-computer interface technology, differentiating itself from the invasive approaches prevalent internationally [1] - The company's offerings cover a comprehensive range of rehabilitation scenarios, including occupational therapy, motor therapy, cognitive speech, and swallowing [1] Market Position and Development - The company has made investments in technology, products, and market channels related to brain-computer interfaces, establishing a certain level of market presence [1] - However, the company faces challenges with delayed bidding and sales processes, which may impact revenue generation [1] - As of the end of 2025, the company does not expect to achieve large-scale sales of related products, resulting in a small proportion of revenue contribution [1]

Group 1 - The core viewpoint of the article emphasizes the importance of timely and relevant research reports in identifying investment opportunities, particularly in emerging fields like brain-computer interfaces [1] - Neuralink, led by Elon Musk, is set to begin large-scale production of brain-computer interface devices in 2026, marking a significant milestone in the integration of life sciences and information technology [1] - The brain-computer interface sector is experiencing rapid technological advancements and policy support, with expectations for commercialization to expand into AI applications and robotics by 2026 [1] Group 2 - The article highlights five key focus areas for investment as the humanoid robot sector approaches critical production milestones, with supply chains becoming more consolidated [2] - The AI wave is driving significant increases in storage prices, with DRAM prices soaring by 171.8%, while domestic wafer manufacturers are accelerating "domestic substitution" in response to tightening overseas restrictions [2] - New policies in Guangdong are encouraging insurance capital to enter the market, providing a dual boost to insurance stocks through asset and liability management [2] - A major state-owned enterprise has invested 1 billion in Thunderbird Innovation, signaling an imminent explosion in the AI glasses sector [2]

Core Viewpoint - The stock of Xiangyu Medical has experienced unusual fluctuations due to increased market attention on brain engineering and brain-computer interface concepts, leading to significant price increases in related sectors [1] Company Focus - The company primarily focuses on non-invasive brain-computer interface technology, covering a comprehensive range of rehabilitation scenarios including occupational therapy, motor therapy, cognitive speech, and swallowing [1] - This approach differs from the current international trend towards invasive brain-computer interface technologies [1] Market Position and Development - The company has made certain advancements in technology, products, and market channels related to brain-computer interfaces [1] - However, the bidding and sales processes exhibit a lag, and as of the end of 2025, related products are not expected to achieve large-scale sales, resulting in a small revenue contribution [1]